@misc{10481/73916,
year = {2022},
month = {2},
url = {http://hdl.handle.net/10481/73916},
abstract = {The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the
duration of this. This is the case of mRNA vaccines such as Moderna’s mRNA-1273. Therefore, it is necessary to study
the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal
response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent
infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601
health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of
100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 postvaccination.
Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular
response of 86% at three months after the second dose, which is related to low humoral response.},
organization = {Investigacion y Desarrollo (I + D) del Sistema Andaluz de Salud (SAS)},
organization = {Instituto de Salud Carlos III
European Commission	FIS PI21/01708},
publisher = {John Wiley & Sons},
keywords = {Moderna vaccine},
keywords = {Humoral response},
keywords = {SARS-CoV-2},
keywords = {mRNA vaccines},
keywords = {mRNA-1273 vaccine},
title = {Study of humoral and cellular immunity in vaccinated with mRNA-1273},
doi = {10.1111/apm.13215},
author = {Gutiérrez Bautista, Juan Francisco and López Nevot, Miguel Ángel and Gómez Vicente, Esther and Quesada, Trinidad and Marín, Eva María and Rodríguez, Ana and Rodríguez, Ana Isabel and Rodríguez Granger, Javier and Cobo, Fernando and Sampedro, Antonio},
}